165 related articles for article (PubMed ID: 37319107)
1. A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis.
Wollenberg A; Thyssen JP; Bieber T; Chan G; Kerkmann U
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2041-2046. PubMed ID: 37319107
[TBL] [Abstract][Full Text] [Related]
2. Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis.
Ertus C; Scailteux LM; Lescoat A; Berthe P; Auffret V; Dupuy A; Oger E; Droitcourt C
Br J Dermatol; 2023 Sep; 189(4):368-380. PubMed ID: 37410552
[TBL] [Abstract][Full Text] [Related]
3. Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case-time control study and a nested case-control study based on the French national health insurance (SNDS) cohort.
Berthe P; Scailteux LM; Lescoat A; Staumont D; Coiffier G; Guéret P; Dupuy A; Oger E; Droitcourt C
BMJ Open; 2022 Sep; 12(9):e059979. PubMed ID: 36130766
[TBL] [Abstract][Full Text] [Related]
4. How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits.
Alduraibi FK; Singh JA
Curr Rheumatol Rep; 2023 Dec; 25(12):295-306. PubMed ID: 38102522
[TBL] [Abstract][Full Text] [Related]
5. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
6. Role of Janus Kinase inhibitors in rheumatoid arthritis treatment.
Reddy V; Cohen S
Curr Opin Rheumatol; 2021 May; 33(3):300-306. PubMed ID: 33767091
[TBL] [Abstract][Full Text] [Related]
7. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.
Atzeni F; Popa CD; Nucera V; Nurmohamed MT
Expert Rev Clin Immunol; 2022 Mar; 18(3):233-244. PubMed ID: 35129033
[TBL] [Abstract][Full Text] [Related]
8. [Rheumatoid arthritis: Appraisement of the new security warnings for JAK-inhibitors].
Fiehn C
Dtsch Med Wochenschr; 2024 Mar; 149(6):326-330. PubMed ID: 38412990
[TBL] [Abstract][Full Text] [Related]
9. Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.
Solitano V; Facheris P; Petersen M; D'Amico F; Ortoncelli M; Aletaha D; Olivera PA; Bieber T; Ramiro S; Ghosh S; D'Agostino MA; Siegmund B; Chary-Valckenaere I; Hart A; Dagna L; Magro F; Felten R; Kotze PG; Jairath V; Costanzo A; Kristensen LE; Biroulet LP; Danese S
Autoimmun Rev; 2024 Mar; 23(3):103504. PubMed ID: 38128748
[TBL] [Abstract][Full Text] [Related]
10. Characterizing real world safety profile of oral Janus kinase inhibitors among adult atopic dermatitis patients: evidence transporting from the rheumatoid arthritis population.
Montez-Rath ME; Lubwama R; Kapphahn K; Ling AY; LoCasale R; Robinson L; Chandross KJ; Desai M
Curr Med Res Opin; 2022 Aug; 38(8):1431-1437. PubMed ID: 35699028
[TBL] [Abstract][Full Text] [Related]
11. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.
Min HK; Kim H; Jeong HJ; Kim SH; Kim HR; Lee SH; Lee K; Shin SA; Park JH
Epidemiol Health; 2023; 45():e2023045. PubMed ID: 37080728
[TBL] [Abstract][Full Text] [Related]
12. Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis.
Palominos PE; Lineburger IB; Xavier RM
Expert Opin Emerg Drugs; 2021 Sep; 26(3):303-321. PubMed ID: 34365877
[TBL] [Abstract][Full Text] [Related]
13. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
Alten R; Mischkewitz M; Stefanski AL; Dörner T
Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
[TBL] [Abstract][Full Text] [Related]
14. Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study.
Song YJ; Cho SK; You SH; Kim JY; Kim H; Jung SY; Sung YK
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36549855
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis.
Venetsanopoulou AI; Voulgari PV; Drosos AA
Expert Rev Clin Immunol; 2022 May; 18(5):485-493. PubMed ID: 35535405
[TBL] [Abstract][Full Text] [Related]
16. The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases.
Singh JA
BioDrugs; 2023 Sep; 37(5):625-635. PubMed ID: 37351790
[TBL] [Abstract][Full Text] [Related]
17. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
Mori S; Ogata F; Tsunoda R
Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of Janus Kinase inhibitor selectivity.
Choy EH
Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
[TBL] [Abstract][Full Text] [Related]
19. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors that Impact Treatment with Oral Janus Kinase Inhibitors Among Adult Patients with Atopic Dermatitis: A Nationwide Registry Study.
Vittrup I; Thein D; Thomsen SF; Egeberg A; Thyssen JP
Acta Derm Venereol; 2024 Jan; 104():adv18638. PubMed ID: 38248914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
